Neuropace Inc (NPCE) Stock Price, Quote & News

Company Profile

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data m...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 237 2700

Fax: 650 237 2701

Website: www.neuropace.com

Address:

455 North Bernardo Avenue, Mountain View, United States

EquityEnforcer Feb. 4 at 4:07 PM

$NPCE is a medical device or healthcare services company; its performance would be tied to factors like patient volumes, reimbursement rates, or product adoption.

0 · Reply

IncognitoBull Jan. 30 at 1:24 PM

$NPCE if you believe in NPCE, you should also check out $NMTC competing tech, we are just getting to commercialization, but, our tech is targeting additional uses, brain, pain, and drug delivery. Ground floor prices vs a weighted top.

0 · Reply

OfficialStocktwitsUser Jan. 26 at 7:42 PM

$NPCE RSI: 54.51, MACD: 0.3089 Vol: 0.62, MA20: 16.40, MA50: 15.88 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Grubnednarb Jan. 8 at 3:47 AM

$NPCE

0 · Reply

Scoops1212 Jan. 7 at 6:05 PM

$NPCE This is about as frustrating of a stock that you can own. I’ve crunched all the numbers and this should be at 40+ right now there is something holding this price down, and it’s not visible in the numbers. Check their quarterly, and some big investors holding their position. When will this launch, as it’s long overdue?

0 · Reply

OfficialStocktwitsUser Dec. 29 at 11:20 AM

$NPCE RSI: 44.41, MACD: 0.5827 Vol: 0.38, MA20: 16.25, MA50: 13.84 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

erevnon Dec. 16 at 3:31 PM

UBS maintains NeuroPace $NPCE at Buy and raises the price target from $18 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Dec. 16 at 2:27 PM

UBS has adjusted their stance on NeuroPace ( $NPCE ), setting the rating to Buy with a target price of 18 → 22.

0 · Reply

JarvisFlow Dec. 10 at 4:00 PM

JP Morgan has updated their rating for NeuroPace ( $NPCE ) to Overweight with a price target of 20.

0 · Reply

SuperGreenToday Dec. 9 at 9:37 PM

$NPCE Share Price: $16.26 Contract Selected: May 15, 2026 $17.5 Calls Buy Zone: $0.73 – $0.90 Target Zone: $1.36 – $1.66 Potential Upside: 76% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 7:30 AM EST - 22 days ago

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

Dec 31, 2025, 9:00 AM EST - 5 weeks ago

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 8:00 AM EST - 7 weeks ago

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

Dec 8, 2025, 8:00 AM EST - 2 months ago

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

Dec 2, 2025, 8:01 AM EST - 2 months ago

NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

Nov 24, 2025, 8:00 AM EST - 2 months ago

NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

Nov 4, 2025, 11:06 PM EST - 3 months ago

NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 3 months ago

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Oct 22, 2025, 8:00 AM EDT - 3 months ago

NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

Aug 28, 2025, 8:00 AM EDT - 5 months ago

NeuroPace to Participate in Upcoming Healthcare Conferences

Aug 12, 2025, 9:50 PM EDT - 6 months ago

NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 6 months ago

NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Aug 1, 2025, 7:30 AM EDT - 6 months ago

NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases

Jun 24, 2025, 4:05 PM EDT - 8 months ago

NeuroPace Announces Strategic CFO Transition

Jun 24, 2025, 3:42 AM EDT - 8 months ago

NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm

Jun 13, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect

Jun 12, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach Out

Jun 11, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation

Jun 10, 2025, 10:00 AM EDT - 8 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 9, 2025, 10:00 AM EDT - 8 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Investors to Connect

Jun 6, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Stockholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Investors to Learn More About the Investigation

Jun 4, 2025, 4:09 PM EDT - 8 months ago

NeuroPace Secures Up to $75 Million in Debt Financing

Jun 3, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Stockholders to Reach Out

Jun 2, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect

Jun 1, 2025, 10:00 AM EDT - 8 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Stockholders to Learn More About the Investigation

May 29, 2025, 12:45 PM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Investors to Inquire about Securities Investigation

May 27, 2025, 12:48 PM EDT - 9 months ago

Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?

May 27, 2025, 8:00 AM EDT - 9 months ago

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

May 13, 2025, 10:33 PM EDT - 9 months ago

NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 9 months ago

NeuroPace Reports First Quarter 2025 Financial Results

Apr 14, 2025, 4:05 PM EDT - 10 months ago

NeuroPace Provides Update on Tariff Status

Apr 8, 2025, 8:00 AM EDT - 10 months ago

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

Apr 3, 2025, 8:00 AM EDT - 10 months ago

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

Apr 2, 2025, 4:05 PM EDT - 10 months ago

NeuroPace Announces Refocusing of Product Portfolio

EquityEnforcer Feb. 4 at 4:07 PM

$NPCE is a medical device or healthcare services company; its performance would be tied to factors like patient volumes, reimbursement rates, or product adoption.

0 · Reply

IncognitoBull Jan. 30 at 1:24 PM

0 · Reply

OfficialStocktwitsUser Jan. 26 at 7:42 PM

0 · Reply

Grubnednarb Jan. 8 at 3:47 AM

$NPCE

0 · Reply

Scoops1212 Jan. 7 at 6:05 PM

0 · Reply

OfficialStocktwitsUser Dec. 29 at 11:20 AM

0 · Reply

erevnon Dec. 16 at 3:31 PM

UBS maintains NeuroPace $NPCE at Buy and raises the price target from $18 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Dec. 16 at 2:27 PM

UBS has adjusted their stance on NeuroPace ( $NPCE ), setting the rating to Buy with a target price of 18 → 22.

0 · Reply

JarvisFlow Dec. 10 at 4:00 PM

JP Morgan has updated their rating for NeuroPace ( $NPCE ) to Overweight with a price target of 20.

0 · Reply

SuperGreenToday Dec. 9 at 9:37 PM

0 · Reply

stockwitsuser2449 Dec. 1 at 12:35 PM

$NPCE

0 · Reply

stockwitsuser2449 Nov. 20 at 7:07 PM

$NPCE large drop here

1 · Reply

HypnoTrader Nov. 19 at 6:48 PM

$NPCE no way to confirm anything an anonymous account is telling you, but the chart seems to agree....

1 · Reply

HypnoTrader Nov. 19 at 6:46 PM

$NPCE

0 · Reply

johnemac Nov. 19 at 6:45 PM

$NPCE In a sample size of one my son continues to be seizure-free since February and his RNS (NPCE's main product) surgery. In addition he is able now to wean back his meds considerably. Thank you Neuropace.

0 · Reply

Scoops1212 Nov. 19 at 3:01 PM

$NPCE If you believe in the treatment, this is the time to go big. The numbers show this should be at $40, and is at $13. I’m not a pumper, and know how to crunch these numbers. This should be at $40 right now!

0 · Reply

stockwitsuser2449 Nov. 15 at 6:01 PM

$NPCE 15 strike put options working out so far

0 · Reply

Scoops1212 Nov. 12 at 2:05 PM

$NPCE The big question is what does this company have to do financially, to beat their opening price over 4 years ago? They’ve had strong quarterly’s all but once, and they had never reached $20. What da?!

0 · Reply

Joby099 Nov. 7 at 2:03 PM

$PLRZ $RIGL $NPCE $LITE

0 · Reply

stockwitsuser2449 Nov. 7 at 12:29 PM

$QURE $BIOA $DYN and $NPCE now. glta

0 · Reply

Joby099 Nov. 7 at 2:21 AM

$PLRZ $RIGL $NPCE $LITE

0 · Reply

Market Cap	503.95M
Revenue (ttm)	79.91M
Net Income (ttm)	-27.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-33.96%
Debt to Equity Ratio	3.17

Volume	102,411
Avg Vol	236,432
Day's Range	N/A - N/A
Shares Out	33.31M
Stochastic %K	51%
Beta	1.85
Analysts	Strong Sell
Price Target	$19.38